Table 4 Clinical and laboratory features... | American Society of Hematology

Table 4

Clinical and laboratory features of the 67 VWD2B patients, according to platelet levels

	Platelet count ≥140 × 10³/μL (n = 47)	Platelet count <140 × 10³/μL (n = 20)
Sex (M/F)	20/27	7/13
Median age, y* (range)	39 (6-87)	55 (8-75)
Median bleeding severity score† (range)	4 (0-24)	9 (2-19)
VWF:RCo, IU/dLMedian (range)	24 (6-105)	24 (6-125)
Patient-months	917	162
No. of bleeding episodes‡	12	17
Incidence of bleeding, % patient-months (95% CI)	1.3 (0.7-2.2)	10.4 (6.0-16.1)

	Platelet count ≥140 × 10³/μL (n = 47)	Platelet count <140 × 10³/μL (n = 20)
Sex (M/F)	20/27	7/13
Median age, y* (range)	39 (6-87)	55 (8-75)
Median bleeding severity score† (range)	4 (0-24)	9 (2-19)
VWF:RCo, IU/dLMedian (range)	24 (6-105)	24 (6-125)
Patient-months	917	162
No. of bleeding episodes‡	12	17
Incidence of bleeding, % patient-months (95% CI)	1.3 (0.7-2.2)	10.4 (6.0-16.1)

Mann-Whitney U test: P = .047.

Mann-Whitney U test: P = .010.

In the calculation of bleeding incidence, only the first bleeding episode after the start of follow-up is counted.